Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

S, Zeuzem; GM, Dusheiko; R, Salupere; A, Mangia; R, Flisiak; RH, Hyland; A, Illeperuma; E, Svarovskaia; DM, Brainard; WT, Symonds; GM, Subramanian; JG, McHutchison; O, Weiland; HW, Reesink; P, Ferenci; C, Hézode; R, Esteban

doi:10.1056/nejmoa1316145

Public

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

Published in The New England journal of medicine • May 4, 2014

NobleIDark:/48914/w1/20260526/AE7C7AB3Record on NobleID

Authors:

Zeuzem S

,

Dusheiko GM

,

Salupere R

Abstract

Background In clinical trials, treatment with a combination of the nucleotide polymerase inhibitor sofosbuvir and the antiviral drug ribavirin was associated with high response rates among patients with hepatitis C virus (HCV) genotype 2 infection, with lower response rates among patients with HCV g...

Discussions